NLS Alvotech

Alvotech and Oaktree Acquisition Corp II establish financing facilities to enhance the company’s capital position and to replace any redeemed capital as part of their proposed merger. The two parties agree to reduce the minimum cash condition outlined in the merger agreement, thereby enhancing deal certainty in their proposed business combination. In late 2021, Alvotech […]

Alvotech and Oaktree Acquisition Corp II, a special purpose acquisition company sponsored by an affiliate of Oaktree Capital Management, have entered into a definitive merger agreement. Upon completion of the transaction, the combined company’s securities are expected to be traded on NASDAQ under the symbol “ALVO.” “Alvotech is in a unique position to impact the […]

Alvotech and Alvotech & CCHT Biopharmaceutical, which is the China joint venture company of Alvotech hf. and Changchun High & New Technology Industries (Group) Inc., have partnered with Yangtze River Pharmaceutical Group to form an exclusive strategic partnership for the commercialization of eight biosimilar medicines in China. The initial pipeline contains biosimilar candidates for treatment […]

Alvotech and DKSH have announced an expansion of their strategic partnership to commercialize six new biosimilar product candidates for the Asian markets. The initial pipeline contains biosimilar candidates addressing multiple therapeutic areas. “We have been delighted to work with DKSH since our initial partnership began earlier this year. The partnership is designed to accelerate improved […]

The collaboration, announced in August, is one of the broadest partnerships within the U.S. biosimilar industry to date to accelerate improved patient access for high quality biosimilar medicines in the U.S. biosimilar industry. Alvotech and Teva Pharmaceutical Industries have entered into an exclusive strategic partnership for the commercialization in the U.S. of five biosimilar product […]